DXCM Stock Chart & Stats
$1529.00
-$123.00(-9.06%)
At close: 4:00 PM EDT
$1529.00
-$123.00(-9.06%)
Day’s Range― - ―
52-Week Range$990.00 - $1,664.99
Previous CloseN/A
Volume160.00
Average Volume (3M)59.00
Market Cap
$576.57B
Enterprise Value$32.67B
Total Cash (Recent Filing)$1.82B
Total Debt (Recent Filing)$1.39B
Price to Earnings (P/E)31.8
Beta0.39
Next Earnings
Feb 11, 2027EPS Estimate
13.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.59
Shares Outstanding377,360,780
10 Day Avg. Volume88
30 Day Avg. Volume59
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)9.43
Price to Sales (P/S)5.56
P/FCF Ratio24.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,868.22Price Target Upside22.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)50.23
Revenue Forecast (FY)$98.26B
Bulls Say, Bears Say
Bulls Say
Recurring CGM RevenueDexcom’s sensor replacement cycle creates recurring revenue and supports customer retention after initial adoption. This model provides a durable base for forecasting, while ongoing reimbursement, channel access, and connected-care partnerships can expand utilization and deepen the value of each customer relationship.
Revenue And Margin ExpansionStrong revenue growth alongside high gross and net margins indicates meaningful operating scale and a profitable business model. Continued margin expansion would increase internal funding for product development, international expansion, and digital initiatives while strengthening Dexcom’s ability to compete over the next several quarters.
Market Share And Clinical StrengthShare gains across customer segments, supported by strong clinical evidence, reinforce Dexcom’s product credibility with patients, clinicians, and reimbursement bodies. This combination can support durable adoption, broaden use among type 2 customers, and strengthen the company’s competitive position in CGM.
Bears Say
Weaker Cash ConversionRecent deterioration in cash conversion means reported earnings are translating into less incremental cash than before. Although absolute cash generation remains substantial, higher investment or working-capital needs could reduce funding available for expansion, buybacks, and other capital-allocation priorities.
Slower International GrowthSlower international growth creates a drag on consolidated expansion and shows that reimbursement-driven gains may not repeat evenly across markets. A prolonged normalization period could delay the benefits of global scale, limit geographic diversification, and require continued investment to rebuild adoption momentum.
Preferred PBM Access LossLoss of preferred access can raise patient costs and make Dexcom’s products less attractive for affected members, creating friction in new starts and retention. Even with a limited direct revenue exposure, the issue increases reliance on alternative pathways such as medical benefits and Dexcom Direct.
Dexcom News
DXCM FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest stock price was $990.00 and its highest was $1664.99 in the past 12 months.
What is Dexcom’s market cap?
Dexcom’s market cap is $576.57B.
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Feb 11, 2027 which is in 102 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Oct 29, 2026. The company reported $13.714 earnings per share for the quarter, beating the consensus estimate of $12.681 by $1.033.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is 13.47.
How many shares outstanding does Dexcom have?
Dexcom has 377,360,780 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $13.714 in its last earnings report, beating expectations of $12.681. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Dexcom?
Currently, no hedge funds are holding shares in MX:DXCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dexcom Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,868.22 (22.19% Upside)
$1,868.22 (22.19% Upside)
Blogger Sentiment
Bullish
MX:DXCM Sentiment 77%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.65%
12-Months-Change
Fundamentals
Return on Equity
36.50%
Trailing 12-Months
Asset Growth
-16.82%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Dexcom
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
DXCM Company Deck
DXCM Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive. Dexcom reported 11% worldwide revenue growth, 14% U.S. growth, continued market-share gains, near-record new patient starts, significant gross-margin and EBITDA-margin expansion, strong cash generation, raised operating and EBITDA margin guidance, and substantial progress in clinical evidence, product launches, manufacturing, and future access expansion. The main challenges were slower international growth, near-term Ireland ramp effects, incremental foreign-exchange headwinds, higher operating expenses, and the loss of preferred access under a PBM representing less than 4% of U.S. revenue. Highlights significantly outweighed the lowlights.View all MX:DXCM earnings summariesDXCM Revenue Breakdown
71.53% U.S.
28.47% International
DXCM Stock 12 Month Forecast
Average Price Target
$1,868.22
▲(22.19% Upside)
Technical Analysis
Abbott Laboratories
―
Insulet
―
Medtronic
―
Tandem Diabetes Care
―
Senseonics Holdings
―